Market instability expected from South Korea’s new pricing reform in 2026-2028
Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the actual…
Pricing and Market Access
Have originator medicines’ list prices started to drop in the US?
Transformative arrival of oral weight loss medicines in the US
US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
China releases 2025 NRDL and first commercial insurance drug list
Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
